Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price trimmed by Wells Fargo & Company from $57.00 to $48.00 in a research report sent to investors on Thursday morning, Benzinga reports. The firm currently has an equal weight rating on the stock. Other equities analysts have also recently issued research reports about the stock. […]
Needham & Company LLC Reiterates Buy Rating for Apellis Pharmaceuticals (NASDAQ:APLS) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Investment analysts at Wedbush dropped their FY2025 EPS estimates for Apellis Pharmaceuticals in a report released on Wednesday, April 17th. Wedbush analyst L. Chico now expects that the company will earn $2.23 per share for the year, down from their prior estimate of $2.24. Wedbush currently has […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) CFO Timothy Eugene Sullivan sold 4,000 shares of Apellis Pharmaceuticals stock in a transaction on Monday, April 1st. The stock was sold at an average price of $58.66, for a total transaction of $234,640.00. Following the sale, the chief financial officer now directly owns 93,338 shares of […]
Apellis Pharmaceuticals, Inc (NASDAQ:APLS) CFO Sells $234,640 00 in Stock themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.